Endomag develops magnetic sensing technologies for breast cancer localisation and staging, centered on its Sentimag® platform. Its core products include the Sentimag® localisation system, the Magseed® magnetic seed for tumour localisation, and Magtrace® liquid tracer for lymph node mapping. The company says its technologies have helped over 130,000 women worldwide and have enabled procedures such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB) that can reduce surgical invasiveness. Endomag plans to use new capital to expand access to advanced techniques (TAD and dSLNB), scale its product offering, market reach and workforce. It continues to invest in research and development and expects to launch a next‑generation Sentimag® platform and new Magseed® products in 2021. Headquartered in Cambridge, UK, with an office in Austin, Texas, the company currently operates in 43 countries and aims to expand further. Endomagnetics develops magnetic-sensing tools and the Sentimag® platform (including the Magseed® magnetic marker) for minimally invasive surgical guidance to localize breast cancers and sentinel nodes. Its technology aims to replace wire placement with a patient-centred clip/marker workflow that improves accuracy, safety, and efficiency. The company reports its products have been used in over 35,000 procedures across 300 hospitals in more than 30 countries. With recent regulatory progress (a 510(k) FDA clearance to extend Magseed use) Endomag is positioned to expand in the U.S. and other markets. The business plans to rapidly expand commercial activity and pursue planned product development to treat more cancer patients worldwide. Financially, the company has raised additional capital to support scaling its commercial operations and R&D.

Total raised

$30M

Funding rounds

2

Latest round

Series D

Latest activity

Nov 2020